Physician profile
Michael D Chacey
NPI 1316069487
$9,333.75
in general payments reported to CMS, 2019-2025
28 companies · $198 in 2025
The $198 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,441 · 2020: $162 · 2021: $338 · 2022: $4,324 · 2023: $489 · 2024: $382 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,842.57 | 2022 | |
| Covidien Lp | $3,204.66 | 2019 | |
| Genzyme Corporation | $334.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $318.12 | 2020-2025 | Breztri, Fasenra, Imfinzi |
| Grifols USA, LLC | $254.59 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.39 | 2021-2025 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Glaxosmithkline, LLC. | $173.41 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $152.32 | 2022-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $108.98 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $88.17 | 2019-2023 | Opsumit |
| Genentech USA, INC. | $79.99 | 2020-2024 | Xolair |
| Insmed, INC. | $66.21 | 2019-2024 | Arikayce |
| United Therapeutics Corporation | $64.73 | 2021-2023 | |
| Pulmonx Corporation | $61.46 | 2019-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mallinckrodt Hospital Products INC. | $59.05 | 2020-2023 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54.80 | 2022-2023 | Tezspire |
| Merck Sharp & Dohme LLC | $40.63 | 2021-2023 | Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $36.40 | 2021-2024 | |
| Ambu INC. | $25.95 | 2023 | |
| Shire North American Group INC | $22.95 | 2019 | |
| Abbvie INC. | $21.17 | 2021 | |
| Shionogi INC | $20.57 | 2022 | |
| Astellas Pharma US INC | $18.24 | 2023 | Cresemba |
| Sunovion Pharmaceuticals INC. | $16.50 | 2020 | |
| Jazz Pharmaceuticals INC. | $16.14 | 2020 | |
| Bard Access Systems, INC. | $16.11 | 2019 | |
| Circassia INC. | $15.98 | 2019 | |
| Mylan Specialty L.P. | $12.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.